|
KMID : 1084220210280020068
|
|
Journal of Rheumatic Diseases
2021 Volume.28 No. 2 p.68 ~ p.75
|
|
|
Health-related Quality of Life Outcomes of Adalimumab for Patients With Rheumatoid Arthritis in Korea
|
|
Lee Myeung-Su
Lee Chang-Hoon
Lee Hye-Soon
Sung Yoon-Kyoung
Choi Jung-Ran
Park Kyung-Su
Lim Mi-Kyoung
Choi Byoong-Yong
Kim Hyoun-Ah
Choi Seung-Won
Lee Yu-Sun
Yoo Wan-Hee
|
|
|
Abstract
|
|
|
Objective: Rheumatoid arthritis (RA) is a chronic, progressive, autoimmune disorder that impairs patients’ overall health-related quality of life (HRQOL). In this study, we evaluated the effect of adalimumab in Korean patients with active RA on HRQOL.
Methods: Patients included in the study had moderate to severe active RA that did not respond to conventional drugs with a Disease Activity Score of 28 joints ＞3.2 and were biologics-naive. All patients received adalimumab 40 mg subcutaneously every other week and were followed for 24 weeks. The primary endpoint was the change in baseline Health Assessment Questionnaire Disability Index (HAQ-DI) score at week 24. Secondary endpoints were changes in the EuroQol 5-dimension 3-Level (EQ-5D-3L) baseline score and Short Form 36-Item Health Survey (SF-36) domain scores at weeks 12 and 24 and change in baseline HAQ-DI score at week 12.
Results: In total, 91 Korean patients were included. Ninety-three percent of patients were in high disease activity with a baseline mean DAS28 value of 6.1 within all patients. The mean change from baseline in HAQ-DI scores were ?0.46 at week 12 and∼0.67 at week 24 (p＜0.0001). Additionally, EQ-5D-3L score at weeks 12 and 24 had significantly improved (p＜0.0001) compared to baseline. SF-36 at weeks 12 and 24 had significantly improved (p＜0.0001, p=0.0001) compared to baseline.
Conclusion: Treatment with adalimumab resulted in significant improvement in HAQ-DI, EQ-5D-3L, and SF-36 scores at 12 and 24 weeks in Korean RA patient.
|
|
|
KEYWORD
|
|
|
Adalimumab, Patients, Quality of life, Rheumatoid arthritis, Antirheumatic agents
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|